2. Gene
  3. EGFR - epidermal growth factor receptor Gene

EGFR - epidermal growth factor receptor Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：表皮生长因子受体

种属: Canis lupus familiaris (sub-species: familiaris)

基因 ID: 404306 | 基因类型: protein coding

关于 EGFR

Primary_assembly 18: 5,890,228-6,085,544 forward strand.ROS_Cfam_1.0:CM025117.1

This gene has 2 transcripts (splice variants), 283 orthologues and 54 paralogues.

EGFR 基因产物(3)

mRNA Protein Name
XM_038423674.1 XP_038279602.1 epidermal growth factor receptor isoform X1
XM_038423675.1 XP_038279603.1 epidermal growth factor receptor isoform X2
XM_038423676.1 XP_038279604.1 epidermal growth factor receptor isoform X2

EGFR 蛋白结构

Recep_L_domain

Recep_L_domain: pfam01030 (56 - 167)

Furin-like

Furin-like: pfam00757 (184 - 334)

Recep_L_domain

Recep_L_domain: pfam01030 (360 - 480)

GF_recep_IV

GF_recep_IV: pfam14843 (504 - 636)

TM_EGFR-like

TM_EGFR-like: cl17045 (633 - 676)

PTKc_EGFR

PTKc_EGFR: cd05108 (703 - 1015)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1000
  • 1207 a.a.
蛋白主名 其他名称

epidermal growth factor receptor

epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)

重组 EGFR 蛋白

目录号 产品名 蛋白编号 纯度
HY-P72986 EGFR Protein, Canine (sf9, His) XP_533073.3 (M1-S618) ≥95%

相关产品

Approval
生物活性分子 (43)
目录号 产品名 作用方式
纯度 是否罕见病
HY-15772 Osimertinib Inhibitor 99.96% 是
HY-50895 Gefitinib Inhibitor 99.94% 是
HY-50896 Erlotinib Inhibitor 99.99% 是
HY-10261 Afatinib Inhibitor 99.93% 是
HY-138298A Trastuzumab deruxtecan Inhibitor 99.90% 否
HY-50898 Lapatinib Inhibitor 99.83% 是
HY-32721 Neratinib Inhibitor 99.59% 是
HY-P9921 Trastuzumab emtansine Inhibitor 99.74% 否
HY-16069 Tucatinib Inhibitor 99.82% 是
HY-138298 Trastuzumab deruxtecan (solution) Inhibitor 99.64% 否
HY-13272 Dacomitinib Inhibitor 99.74% 是
HY-P9985 Disitamab vedotin Inhibitor ≥99.0% 否
HY-15772A Osimertinib mesylate Inhibitor 99.95% 是
HY-135815 Mobocertinib Inhibitor 99.60% 是
HY-12008 Erlotinib Hydrochloride Inhibitor 99.93% 是
HY-104065 Pyrotinib Inhibitor 99.80% 否
HY-112870A Firmonertinib mesylate Inhibitor 99.97% 否
HY-109061 Lazertinib Inhibitor 99.07% 否
HY-112823 Almonertinib Inhibitor 99.98% 否
HY-15164A Icotinib Inhibitor 99.99% 是
HY-50895A Gefitinib hydrochloride Inhibitor 99.85% 是
HY-N0281 Daphnetin Inhibitor 99.86% 否
HY-10261A Afatinib dimaleate Inhibitor 99.88% 是
HY-19730 Olmutinib Inhibitor 99.88% 否
HY-50898A Lapatinib ditosylate Inhibitor 99.98% 是
HY-79077 Osimertinib dimesylate Inhibitor 99.96% 是
HY-104065B Pyrotinib dimaleate Inhibitor 98.56% 否
HY-15164 Icotinib Hydrochloride Inhibitor 99.81% 是
HY-112823A Almonertinib mesylate Inhibitor 99.85% 否
HY-50898B Lapatinib ditosylate monohydrate Inhibitor 99.78% 是
HY-135815A Mobocertinib succinate Inhibitor 99.61% 是
HY-118263 Dacomitinib hydrate Inhibitor 99.03% 否
HY-112823B Almonertinib hydrochloride Inhibitor 99.77% 否
HY-P9921A Trastuzumab emtansine (solution) 99.01% 否
HY-32721B Neratinib maleate Inhibitor 99.83% 是
HY-10261B (E/Z)-Afatinib Inhibitor 99.98% 否
HY-112870 Firmonertinib Inhibitor / 否
HY-10261D Afatinib oxalate Inhibitor / 否
HY-135815B Mobocertinib mesylate Inhibitor / 否
HY-50895B Gefitinib dihydrochloride Inhibitor / 否
HY-50898C Lapatinib tosylate Inhibitor / 否
HY-50895R Gefitinib (Standard) Inhibitor / 否
HY-12008A Erlotinib mesylate Inhibitor / 否
抗体抑制剂 (8)
目录号 产品名 作用方式
纯度 是否罕见病
HY-P9907 Trastuzumab Inhibitor 99.80% 否
HY-P9905 Cetuximab Inhibitor 99.70% 否
HY-P9912 Pertuzumab Inhibitor 99.80% 否
HY-P9977 Amivantamab Inhibitor 99.90% 否
HY-P99041 Panitumumab Inhibitor 98.80% 否
HY-P9968 Nimotuzumab Inhibitor 96.70% 否
HY-P99030 Margetuximab Inhibitor 98.90% 否
HY-P9964 Necitumumab Inhibitor 95.00% 否
Clinical Phase
生物活性分子 (52)
目录号 产品名 作用方式
纯度 Phase
HY-14596 Genistein Inhibitor 99.86% Phase 4
HY-50895G Gefitinib (GMP) Inhibitor / Phase 4
HY-132842 Sunvozertinib Inhibitor 99.92% Phase 3
HY-15729 Rociletinib Inhibitor 99.79% Phase 3
HY-18750 Zorifertinib Inhibitor 99.76% Phase 3
HY-13314 Tesevatinib Inhibitor 99.21% Phase 3
HY-10530 Varlitinib Inhibitor 98.03% Phase 3
HY-19816A Avitinib maleate Inhibitor ≥98.0% Phase 3
HY-19816 Avitinib Inhibitor 99.90% Phase 3
HY-138751 limertinib Inhibitor 99.12% Phase 3
HY-16069A Tucatinib hemiethanolate Inhibitor 99.97% Phase 3
HY-19803 Naquotinib mesylate Inhibitor 98.02% Phase 3
HY-15729A Rociletinib hydrobromide Inhibitor 98.04% Phase 3
HY-19729 Naquotinib Inhibitor 98.71% Phase 3
HY-144680 BLU-945 Inhibitor 99.90% Phase 2
HY-10367 Canertinib Inhibitor 99.95% Phase 2
HY-32718 Pelitinib Inhibitor 98.80% Phase 2
HY-18957 Lifirafenib Inhibitor 98.73% Phase 2
HY-112299 Zipalertinib Inhibitor 99.81% Phase 2
HY-10333 BMS-690514 Inhibitor 99.07% Phase 2
HY-10045 AEE788 Inhibitor 99.13% Phase 2
HY-136789 Tuxobertinib Inhibitor 99.94% Phase 2
HY-12872 Nazartinib Inhibitor 99.48% Phase 2
HY-12972 Mavelertinib Inhibitor 99.21% Phase 2
HY-19985 PF-06459988 Inhibitor 98.87% Phase 2
HY-10367A Canertinib dihydrochloride Inhibitor 99.12% Phase 2
HY-107367A Epertinib hydrochloride Inhibitor 98.25% Phase 2
HY-17632 Tarloxotinib bromide Inhibitor 99.26% Phase 2
HY-19909 NRC-2694 Antagonist 99.45% Phase 2
HY-107367 Epertinib Inhibitor ≥98.0% Phase 2
HY-12872A Nazartinib mesylate Inhibitor / Phase 2
HY-106204 Nelipepimut-S / Phase 2
HY-10223 CUDC-101 Inhibitor 99.19% Phase 1
HY-13501 Mubritinib Inhibitor 99.91% Phase 1
HY-15196 TAK-285 Inhibitor 99.70% Phase 1
HY-10322 Falnidamol Inhibitor 99.05% Phase 1
HY-B0794B AZ7550 Mesylate Inhibitor 99.24% Phase 1
HY-101820 Simotinib Inhibitor 99.70% Phase 1
HY-12010 BMS-599626 Hydrochloride Inhibitor 99.68% Phase 1
HY-10346A AV-412 free base Inhibitor 98.33% Phase 1
HY-111553 TAS0728 Inhibitor 99.15% Phase 1
HY-103443 HKI-357 Inhibitor 99.65% Phase 1
HY-104066 Theliatinib Inhibitor 99.77% Phase 1
HY-128778 DBPR112 Inhibitor 98.37% Phase 1
HY-139300A Epitinib succinate Inhibitor 99.01% Phase 1
HY-116437 Selatinib Inhibitor 99.83% Phase 1
HY-10346 AV-412 Inhibitor 99.17% Phase 1
HY-B0794A AZ7550 hydrochloride Inhibitor 98.66% Phase 1
HY-15732 BGB-102 Inhibitor 97.10% Phase 1
HY-104066A Theliatinib tartrate / Phase 1
HY-139300 Epitinib Inhibitor / Phase 1
HY-10251 BMS-599626 Inhibitor / Phase 1
抗体抑制剂 (30)
目录号 产品名 作用方式
纯度 Phase
HY-P9907A Trastuzumab (anti-HER2) Inhibitor 99.62% Phase 4
HY-P99854 Disitamab Inhibitor ≥95.0% Phase 4
HY-P99041A Panitumumab (anti-EGFR) Inhibitor 98.00% Phase 4
HY-P99969 Inetetamab Inhibitor 96.54% Phase 4
HY-P99275 Patritumab Inhibitor 98.94% Phase 3
HY-P99380 Zanidatamab Inhibitor 95.06% Phase 3
HY-P99849 Depatuxizumab Inhibitor 99.58% Phase 3
HY-P99155 Zalutumumab 98.26% Phase 3
HY-P99676 Izalontamab Inhibitor 99.03% Phase 3
HY-P99455 Bafisontamab Inhibitor 96.00% Phase 3
HY-P99437 Anbenitamab Inhibitor 99.22% Phase 3
HY-P99831 Coprelotamab / Phase 3
HY-P99630 Gancotamab Inhibitor / Phase 3
HY-P99268 Seribantumab Inhibitor ≥95.0% Phase 2
HY-P99507 Zenocutuzumab Inhibitor 99.20% Phase 2
HY-P99406 Petosemtamab Degrader 95.00% Phase 2
HY-P9969 Matuzumab 98.12% Phase 2
HY-P99936 Elgemtumab Inhibitor 96.80% Phase 2
HY-P99618 Fidasimtamab Inhibitor 95.00% Phase 2
HY-P99216 Ponezumab Inhibitor 99.39% Phase 2
HY-P99866 Duligotuzumab 97.93% Phase 2
HY-P99715 Losatuxizumab Inhibitor 95.00% Phase 2
HY-P990049 Becotatug Inhibitor 98.44% Phase 2
HY-P99296 Intetumumab Inhibitor 99.24% Phase 2
HY-P99605 Cinrebafusp alfa Inhibitor 98.53% Phase 2
HY-P99295 Imgatuzumab Inhibitor / Phase 2
HY-P99628 Futuximab Inhibitor / Phase 2
HY-P99672 Istiratumab Inhibitor / Phase 2
HY-P99304 Lumretuzumab Inhibitor 95.00% Phase 1
HY-P99461 Barecetamab Inhibitor 97.96% Phase 1
Pre-clinical Phase
生物活性分子 (446)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-12000 AG490 Inhibitor 99.97% 否
HY-13524 AG-1478 Inhibitor 99.22% 否
HY-101084 NSC 228155 Activator ≥98.0% 否
HY-13050 Sapitinib Inhibitor 99.93% 否
HY-13595 Chrysophanol Inhibitor 99.77% 否
HY-100848 TX1-85-1 Inhibitor 98.04% 否
HY-16558 Butein Inhibitor 99.95% 否
HY-14346 PD153035 Inhibitor 98.83% 否
HY-N0280 Corosolic acid 99.23% 否
HY-123921 Gefitinib-based PROTAC 3 Inhibitor 99.98% 否
HY-N2409 Delphinidin chloride Inhibitor ≥98.0% 否
HY-100213 EAI045 Inhibitor 99.08% 否
HY-15644 Tyrphostin 23 Inhibitor 99.43% 否
HY-129550 BI-4020 Inhibitor 99.28% 否
HY-B0793 AZ-5104 Inhibitor 99.70% 否
HY-13896 PD168393 Inhibitor 98.60% 否
HY-18609 PD158780 Inhibitor 99.56% 否
HY-14674 CP-724714 Inhibitor 98.53% 否
HY-111138 CZC-8004 Inhibitor 99.81% 否
HY-W016412 Coenzyme Q0 Inhibitor 99.88% 否
HY-12026 WZ4002 Inhibitor 99.76% 否
HY-20878 Tyrphostin AG 879 Inhibitor 99.85% 否
HY-15844 AG-825 Inhibitor 98.02% 否
HY-15730 Poziotinib Inhibitor 99.96% 否
HY-N2450 Sulforaphene Inhibitor 99.80% 否
HY-147183B JBJ-09-063 hydrochloride Inhibitor 99.37% 否
HY-13427 Allitinib tosylate Inhibitor 99.83% 否
HY-13895 WHI-P154 Inhibitor 99.39% 否
HY-12001 WZ-3146 Inhibitor 99.63% 否
HY-109189 Rezivertinib Inhibitor 99.43% 否
HY-P1845A PACAP-38 (31-38), human, mouse, rat TFA Inducer 99.59% 否
HY-135805A (Rac)-JBJ-04-125-02 Inhibitor ≥95.0% 否
HY-150024 BI-4142 Inhibitor 98.39% 否
HY-144880 SC209 Inhibitor 99.52% 否
HY-N1166 Tephrosin ≥97.0% 否
HY-14596R Genistein (Standard) Inhibitor 99.31% 否
HY-P1845 PACAP-38 (31-38), human, mouse, rat Inducer 99.98% 否
HY-10325 CL-387785 Inhibitor 98.05% 否
HY-78869 Mutated EGFR-IN-1 Inhibitor 99.84% 否
HY-19815 Olafertinib Inhibitor 99.51% 否
HY-147183A JBJ-09-063 TFA Inhibitor 99.64% 否
HY-108052 Delphinidin 3-glucoside chloride Inhibitor 99.83% 否
HY-10531 ARRY-380 analog Inhibitor 99.19% 否
HY-14596S Genistein-d4 Inhibitor 98.81% 否
HY-15769 WHI-P180 Inhibitor 99.62% 否
HY-128862 EGFR-IN-7 Inhibitor 99.76% 否
HY-107364 MTX-211 Inhibitor ≥98.0% 否
HY-147941A MS9427 TFA Degrader 99.01% 否
HY-137191 CH7233163 Inhibitor 99.61% 否
HY-101219 VEGFR-IN-1 Inhibitor 98.42% 否
HY-123578 NSC689857 Inhibitor 99.65% 否
HY-43533 Tarlox-TKI Inhibitor 97.03% 否
HY-100434 PD-161570 Inhibitor 99.04% 否
HY-112411 PD 174265 Inhibitor 98.72% 否
HY-12029 WZ8040 Inhibitor 99.22% 否
HY-134877 BAY 2476568 Inhibitor 98.05% 否
HY-150023 BI-1622 Inhibitor 98.97% 否
HY-137433 Befotertinib Inhibitor 99.96% 否
HY-136430 JCN037 Inhibitor 99.76% 否
HY-142283AS Dosimertinib mesylate Inhibitor 99.44% 否
HY-101450 PF-6274484 Inhibitor 98.41% 否
HY-153268 BDTX-1535 Inhibitor 99.03% 否
HY-100499 Tyrphostin AG 528 Inhibitor ≥98.0% 否
HY-101960A Tyrphostin A51 Inhibitor ≥99.0% 否
HY-17499 EGFR-IN-12 Inhibitor 99.40% 否
HY-15801 HG-14-10-04 Inhibitor 99.09% 否
HY-103440 EGFR/ErbB-2/ErbB-4 inhibitor-3 Inhibitor 98.19% 否
HY-132842A (S)-Sunvozertinib Inhibitor 99.14% 否
HY-139920 Oritinib Inhibitor 99.18% 否
HY-138627A AST5902 trimesylate Inhibitor 99.87% 否
HY-N2510 Myristicin Inhibitor 99.89% 否
HY-124813 PDZ1i Inhibitor 99.29% 否
HY-112293 GW2974 99.54% 否
HY-103566 LY456236 Inhibitor 99.81% 否
HY-101042 AG-494 Inhibitor 99.31% 否
HY-B1394 Khellin Inhibitor 99.89% 否
HY-124674A CCT365623 hydrochloride Inhibitor 98.11% 否
HY-117155 PKI-166 Inhibitor 99.58% 否
HY-N0211 Cyasterone Inhibitor 99.58% 否
HY-155537 YK-029A Inhibitor 99.50% 否
HY-112420 EGFR/ErbB-2/ErbB-4 inhibitor-2 Inhibitor 99.69% 否
HY-12008S Erlotinib-d6 hydrochloride Inhibitor 98.13% 否
HY-153110A Larotinib mesylate hydrate Inhibitor 98.66% 否
HY-141481 DP-C-4 Inhibitor 99.72% 否
HY-100962 (E)-AG 99 Inhibitor 98.36% 否
HY-41404 Piperonylic acid 99.86% 否
HY-120590 Ruserontinib Inhibitor 99.82% 否
HY-101429 RG13022 Inhibitor ≥95.0% 否
HY-107459 (E/Z)-AG490 Inhibitor 99.97% 否
HY-150611 EGFR-IN-70 Inhibitor 99.16% 否
HY-18963 Lavendustin A Inhibitor 98.02% 否
HY-112345 PD-089828 Inhibitor 98.07% 否
HY-N4201 β-Hydroxyisovalerylshikonin Inhibitor 99.83% 否
HY-19617B EGFR-IN-1 TFA Inhibitor 99.38% 否
HY-101426 RG14620 Inhibitor 98.09% 否
HY-N6577 Astragaloside VI 99.95% 否
HY-123952 RTC-5 Inhibitor 99.89% 否
HY-12013 PD153035 Hydrochloride Inhibitor 98.78% 否
HY-15772S Osimertinib-d6 Inhibitor 99.97% 否
HY-18603 FIIN-3 Inhibitor 99.66% 否
HY-119944 JND3229 Inhibitor 99.78% 否
HY-147413 Unecritinib Inhibitor 98.83% 否
HY-157229 STX-721 Inhibitor 98.25% 否
HY-100214 EAI001 Inhibitor 99.88% 否
HY-147219A SIAIS164018 hydrochloride Inhibitor 99.84% 否
HY-155079 DZD1516 98.31% 否
HY-W013857 Lavendustin C Inhibitor 98.32% 否
HY-138072 EMI1 Inhibitor 99.78% 否
HY-P1855 HER2/neu (654-662) GP2 98.04% 否
HY-150610 EGFR-IN-69 Inhibitor 99.58% 否
HY-135805B (Rac)-JBJ-04-125-02 acetate 96.58% 否
HY-15772S1 Osimertinib-13C,d3 99.14% 否
HY-P5314 OK2 Inhibitor 95.95% 否
HY-144304 PROTAC EGFR degrader 2 Inhibitor 95.61% 否
HY-13984 Mutant EGFR inhibitor Inhibitor 99.51% 否
HY-103442 CGP52411 Inhibitor 99.82% 否
HY-10261S Afatinib-d6 Inhibitor ≥99.0% 否
HY-153111 EGFR/HER2-IN-9 Inhibitor 98.73% 否
HY-13897 CNX-2006 Inhibitor 98.42% 否
HY-U00002 ZD-4190 Inhibitor 98.08% 否
HY-101041 (E)-AG 556 Inhibitor 99.92% 否
HY-50895S Gefitinib-d8 Inhibitor 98.42% 否
HY-126320 EGFR-IN-8 Inhibitor 98.01% 否
HY-145960 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Agonist 99.39% 否
HY-130608 Mutated EGFR-IN-3 Inhibitor / 否
HY-147183 JBJ-09-063 Inhibitor / 否
HY-147941 MS9427 Degrader 95.29% 否
HY-147219 SIAIS164018 Inhibitor / 否
HY-19617A EGFR-IN-1 hydrochloride Inhibitor / 否
HY-19617 EGFR-IN-1 Inhibitor / 否
HY-130616 EGFR-IN-11 Inhibitor 99.30% 否
HY-115716 EGFR-IN-17 Inhibitor 98.42% 否
HY-135805 JBJ-04-125-02 Inhibitor / 否
HY-133780 Afatinib impurity 11 Inhibitor 99.10% 否
HY-50895S1 Gefitinib-d6 Inhibitor ≥98.0% 否
HY-155358 Os30 Inhibitor 98.34% 否
HY-15336 AG 555 Inhibitor ≥98.0% 否
HY-118532 Tyrphostin AG30 Inhibitor 99.70% 否
HY-B0794 AZ7550 Inhibitor / 否
HY-13272S2 Dacomitinib-d10 dihydrochloride Inhibitor ≥95.0% 否
HY-12872B Nazartinib S-enantiomer 98.66% 否
HY-149636 Multi-target kinase inhibitor 2 Inhibitor 99.82% 否
HY-100923 H-9 Dihydrochloride Inhibitor 98.98% 否
HY-126319 SU5204 Inhibitor 99.46% 否
HY-103439 GW583340 dihydrochloride Inhibitor / 否
HY-144677 pan-HER-IN-2 Inhibitor 98.10% 否
HY-131864 SJF-1528 Degrader / 否
HY-12806 AG1557 Inhibitor 99.63% 否
HY-P2503 EGFR Protein Tyrosine Kinase Substrate 99.05% 否
HY-50896S Erlotinib-d6 Inhibitor / 否
HY-108484 PP 3 Inhibitor 99.79% 否
HY-101007A (+)-Tyrphostin B44 Inhibitor 97.01% 否
HY-157480 EGFR/AURKB-IN-1 Inhibitor / 否
HY-101006 Methyl 2,5-dihydroxycinnamate Inhibitor 99.70% 否
HY-111452 EGFR-IN-85 Inhibitor / 否
HY-103441 JNJ28871063 hydrochloride Inhibitor / 否
HY-157413 YS-67 Inhibitor 99.41% 否
HY-158149 T-1-PMPA Inhibitor 99.70% 否
HY-147942 MS9449 / 否
HY-113599 Isoprocurcumenol Activator 95.41% 否
HY-131865 SJF-1521 Degrader 99.20% 否
HY-101756 SDZ281-977 98.00% 否
HY-138751A limertinib diTFA Inhibitor ≥98.0% 否
HY-18750A Zorifertinib hydrochloride Inhibitor / 否
HY-142283 Dosimertinib Inhibitor / 否
HY-19981B Derazantinib dihydrochloride Inhibitor / 否
HY-135914 JBJ-02-112-05 Inhibitor / 否
HY-163428 ZN-A-1041 Inhibitor / 否
HY-128860 Mutated EGFR-IN-2 Inhibitor / 否
HY-163354 EGFR-IN-103 Inhibitor / 否
HY-143734 HER2-IN-6 / 否
HY-132883 EGFR/CSC-IN-1 Inhibitor / 否
HY-131067 EMI56 Inhibitor 99.72% 否
HY-115951 EGFR/HER2-IN-2 Inhibitor / 否
HY-153110 Larotinib Inhibitor / 否
HY-10407G SU 5402 (GMP) Inhibitor / 否
HY-138627 AST5902 Inhibitor / 否
HY-125841 EGFR mutant-IN-1 Inhibitor / 否
HY-139920A Oritinib mesylate Inhibitor / 否
HY-10530A Varlitinib tosylate Inhibitor / 否
HY-147303 Sacibertinib Inhibitor / 否
HY-131066 EMI48 Inhibitor 99.02% 否
HY-138746 EGFR-IN-15 Inhibitor / 否
HY-144048 EGFR-IN-31 / 否
HY-155285 YS-363 Inhibitor / 否
HY-143729 EGFR-IN-29 Inhibitor / 否
HY-162483 EGFR kinase inhibitor 6 Inhibitor / 否
HY-13272S3 Dacomitinib-d10 Inhibitor / 否
HY-156284 EGFR-IN-89 Inhibitor / 否
HY-100636A Gefitinib N-oxide hydrochloride Inhibitor / 否
HY-158018 EGFR-TK-IN-2 Inhibitor / 否
HY-162482 EGFR kinase inhibitor 5 Inhibitor / 否
HY-158829 SSOe26 sodium / 否
HY-112405 BPIQ-I Inhibitor / 否
HY-153557A HER2-IN-14 Inhibitor / 否
HY-10261AS Afatinib-d6 dimaleate Inhibitor / 否
HY-157402 Topoisomerase II/EGFR-IN-1 / 否
HY-163632 EGFR-IN-112 Inhibitor / 否
HY-100064S1 O-Desmethyl gefitinib-d6 Inhibitor / 否
HY-161536 PROTAC EGFR degrader 9 Inhibitor / 否
HY-147741 DPPY Inhibitor / 否
HY-143246 EGFR kinase inhibitor 1 Inhibitor / 否
HY-158828 SSO111 sodium / 否
HY-158153 EGFR-IN-108 Inhibitor / 否
HY-157399 EGFR/HER2-IN-10 Inhibitor / 否
HY-145823 EGFR-IN-42 Inhibitor / 否
HY-144050 EGFR-IN-33 Inhibitor / 否
HY-152144 EGFR-IN-75 Inhibitor / 否
HY-146239 EGFR/HER2/TS-IN-2 Inhibitor / 否
HY-149556 MTX-241F Inhibitor / 否
HY-149824 EGFR T790M/L858R-IN-2 Inhibitor 99.66% 否
HY-149517 EGFR/BRAFV600E-IN-2 Inhibitor / 否
HY-143323 HER2-IN-9 Inhibitor / 否
HY-103437 EGFR-IN-80 Inhibitor / 否
HY-163402 EGFR-IN-108 chloride Inhibitor / 否
HY-163434 PRMT5/EGFR-IN-1 Inhibitor / 否
HY-148460 Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine Inhibitor / 否
HY-137028 2′-Thioadenosine Inhibitor / 否
HY-158310 SOS1/EGFR-IN-1 Inhibitor / 否
HY-158154 EGFR-IN-110 Inhibitor / 否
HY-156912 Tyrosine kinase-IN-7 Inhibitor 99.25% 否
HY-155227 ALK/EGFR-IN-1 Inhibitor / 否
HY-113549 Erbstatin Inhibitor / 否
HY-157994 EGFR WT/T790M-IN-2 Inhibitor / 否
HY-143337 EGFR-IN-47 Inhibitor / 否
HY-150781 EGFR-IN-71 Inhibitor / 否
HY-141486A PROTAC PARP/EGFR ligand 1 / 否
HY-146474 EGFR-IN-54 Inhibitor / 否
HY-157432 EGFR-IN-97 Inhibitor / 否
HY-147796 EGFR/HER2/CDK9-IN-1 Inhibitor / 否
HY-110333 BMS-599626 dihydrochloride Inhibitor / 否
HY-151882 EGFR-IN-73 Inhibitor / 否
HY-146471 EGFR-IN-51 Inhibitor / 否
HY-158178 EGFR T790M/L858R-IN-7 Inhibitor / 否
HY-144605 PROTAC EGFR degrader 3 Inhibitor 97.39% 否
HY-B0794S AZ7550-d5 Inhibitor / 否
HY-144760 EGFR-IN-3 Inducer / 否
HY-143733 HER2-IN-5 Inhibitor / 否
HY-157324 EGFR-IN-94 Inhibitor / 否
HY-131710 PDE5-IN-3 Inhibitor / 否
HY-142681 EGFR-IN-28 Inhibitor / 否
HY-156114 EGFR/CDK2-IN-2 Inhibitor / 否
HY-152098 HX103 Inhibitor / 否
HY-155736 MAPK-IN-2 Inhibitor / 否
HY-161136 EGFR/STAT3-IN-1 Inhibitor / 否
HY-153744 JGK-068S Inhibitor / 否
HY-P5258 Oligopeptide-41 Inducer / 否
HY-142283BS N-Desmethyl dosimertinib-d5 / 否
HY-118998 TX2-121-1 Inhibitor / 否
HY-162254 EGFR/ACK1-IN-1 Inhibitor / 否
HY-157581 MS39 Degrader / 否
HY-139884 EGFR-IN-18 Inhibitor / 否
HY-158016 Antiproliferative agent-49 Inhibitor / 否
HY-162300 EGFR kinase inhibitor 4 Inhibitor / 否
HY-147967 EGFR-IN-63 Inhibitor / 否
HY-147826 EGFR-IN-60 Inhibitor / 否
HY-50898S3 Lapatinib-d4-1 Inhibitor / 否
HY-W174279 Tyrphostin 8 Inhibitor ≥98.0% 否
HY-114535 Jaceidin Inhibitor / 否
HY-149518 EGFR/BRAFV600E-IN-3 Inhibitor / 否
HY-144676 pan-HER-IN-1 Inhibitor / 否
HY-142680 EGFR-IN-23 Inhibitor / 否
HY-108931 AG 1406 Inhibitor 99.03% 否
HY-147996 EGFR-IN-67 Inhibitor / 否
HY-149695 EGFR-IN-91 Inhibitor / 否
HY-163094 EGFR-IN-95 Inhibitor / 否
HY-144054 EGFR-IN-37 Inhibitor / 否
HY-144052 EGFR-IN-35 Inhibitor / 否
HY-157526 EGFR-TK-IN-1 Inhibitor / 否
HY-142678 EGFR-IN-21 Inhibitor / 否
HY-B0793S1 AZ-5104-d2 Inhibitor / 否
HY-147994 EGFR/HER2-IN-5 Inhibitor / 否
HY-101959 Tyrphostin AG213 Inhibitor / 否
HY-110039 BIBX 1382 dihydrochloride Inhibitor / 否
HY-100064S O-Desmethyl gefitinib-d8 Inhibitor 99.84% 否
HY-161030 EGFR-IN-92 Inhibitor / 否
HY-160564 ZNL-0056 Inhibitor / 否
HY-156457 EGFR-IN-90 Inhibitor / 否
HY-151161 EGFR/HER2-IN-8 Inhibitor / 否
HY-161031 EGFR-IN-93 Inhibitor / 否
HY-101522 CHMFL-EGFR-202 Inhibitor 99.75% 否
HY-100064 O-Desmethyl gefitinib Inhibitor 99.40% 否
HY-158177 EGFR T790M/L858R-IN-6 Inhibitor / 否
HY-142512 EGFR-IN-24 Inhibitor / 否
HY-151156 EGFR/HER2-IN-6 Inhibitor / 否
HY-146782 EGFR-IN-49 Inhibitor / 否
HY-146423 PROTAC EGFR degrader 6 Inhibitor / 否
HY-101960 (Z)-Tyrphostin A51 Inhibitor / 否
HY-146349 PROTAC EGFR degrader 4 Inhibitor / 否
HY-161269 EGFR-IN-101 Inhibitor / 否
HY-151981 EGFR-IN-74 Inhibitor / 否
HY-161408 GePhos1 / 否
HY-162062 EGFR WT/T790M/L858R-IN-1 Inhibitor / 否
HY-163371 EGFR WT/T790M-IN-1 Inhibitor / 否
HY-163417 HER2-IN-15 Inhibitor / 否
HY-13595R Chrysophanol (Standard) Inhibitor / 否
HY-161618 MJ04 Inhibitor / 否
HY-147992 EGFR/HER2-IN-4 Inhibitor / 否
HY-155969 EGFR-IN-83 Inhibitor / 否
HY-155200 EGFR-IN-84 Inhibitor / 否
HY-142283CS N-Methyl-dosimertinib-d5 / 否
HY-157398 EGFR T790M/L858R-IN-3 Inhibitor / 否
HY-137786 EGFR-IN-16 Inhibitor / 否
HY-161319 EGFR-IN-104 Inhibitor / 否
HY-144055 EGFR-IN-38 Inhibitor / 否
HY-144056 EGFR-IN-39 Inhibitor / 否
HY-13524A AG-1478 hydrochloride Inhibitor / 否
HY-W423595 BEBT-109 Inhibitor / 否
HY-10261E (R)-Afatinib Inhibitor / 否
HY-147798 EGFR/HER2/CDK9-IN-3 Inhibitor / 否
HY-156116 EGFR/CDK2-IN-4 Inhibitor / 否
HY-158176 EGFR T790M/L858R-IN-5 Inhibitor / 否
HY-149846 SIQ17 Inhibitor / 否
HY-156741 EGFR-IN-87 Inhibitor / 否
HY-143901 EGFR-IN-40 Inhibitor / 否
HY-161537 EGFR ligand-9 Inhibitor / 否
HY-146210 EGFR-IN-50 Inhibitor / 否
HY-150782 UNC-CA359 Inhibitor / 否
HY-147802 EGFR-IN-59 Inhibitor / 否
HY-161320 EGFR-IN-105 Inhibitor / 否
HY-146136 EGFR-IN-56 Inhibitor / 否
HY-144097 HER2-IN-8 Inhibitor / 否
HY-162148 HNPMI Inhibitor / 否
HY-144444 NSC381467 Inhibitor / 否
HY-151159 DHFR-IN-4 Inhibitor / 否
HY-19985A (3S,4S)-PF-06459988 99.85% 否
HY-163418 HER2-IN-17 Inhibitor / 否
HY-146422 PROTAC EGFR degrader 5 Inhibitor / 否
HY-149407 Multi-kinase-IN-4 Inhibitor / 否
HY-161146 EGFR-IN-100 Inhibitor / 否
HY-153557 HER2-IN-13 Inhibitor / 否
HY-127067 Yuanhuadin Inhibitor / 否
HY-162099 VEGFR-IN-4 Inhibitor / 否
HY-149889 EGFR-IN-78 Inhibitor / 否
HY-144049 EGFR-IN-32 Inhibitor / 否
HY-147997 EGFR-IN-68 Inhibitor / 否
HY-142519 EGFR-IN-27 Inhibitor / 否
HY-162332 EGFR-PK/JNK-2-IN-1 Inhibitor / 否
HY-100636 Gefitinib N-oxide Inhibitor / 否
HY-147995 EGFR-IN-64 Inhibitor / 否
HY-145867 EGFR-IN-45 Inhibitor / 否
HY-145824 EGFR-IN-43 Inhibitor / 否
HY-163453 HER2-IN-19 Inhibitor / 否
HY-151158 EGFR/HER2-IN-7 Inhibitor / 否
HY-161275 BI-4732 Inhibitor / 否
HY-142517 EGFR-IN-25 Inhibitor / 否
HY-160613 EGFR/HER2-IN-11 Inhibitor / 否
HY-146228 HSP90-IN-13 Inhibitor / 否
HY-144445 NSC114126 Inhibitor / 否
HY-153901 PROTAC EGFR degrader 8 Inhibitor / 否
HY-162323 EGFR-IN-106 Inhibitor / 否
HY-151377 RET-IN-19 Inhibitor / 否
HY-143874 HER2-IN-7 Inhibitor / 否
HY-162360 EGFR-IN-109 Inhibitor / 否
HY-163419 HER2-IN-18 Inhibitor / 否
HY-100663 Gefitinib impurity 2 99.56% 否
HY-18213 EGFR-IN-9 Inhibitor 98.84% 否
HY-146238 EGFR/HER2/TS-IN-1 Inhibitor / 否
HY-115933 EGFR/BRAF-IN-1 Inhibitor / 否
HY-144044 EGFR-IN-30 Inhibitor / 否
HY-156470 Multi-kinase-IN-6 Inhibitor / 否
HY-160068 2-2(t) aptamer sodium Chemical / 否
HY-147858 PROTAC EGFR degrader 7 Inhibitor / 否
HY-147825 EGFR/BRAFV600E-IN-1 Inhibitor / 否
HY-157166 EGFR kinase inhibitor 2 Inhibitor / 否
HY-144441 NSC81111 Inhibitor / 否
HY-108016 Peruvoside Inhibitor / 否
HY-145844 EGFR-IN-44 Inhibitor / 否
HY-158175 EGFR T790M/L858R-IN-4 Inhibitor / 否
HY-144794 EGFR-IN-46 Inhibitor / 否
HY-101958 Tyrphostin 25 Inhibitor / 否
HY-P2548 pp60 (v-SRC) Autophosphorylation Site, Phosphorylated / 否
HY-161602 EGFR/HER2-IN-13 Inhibitor / 否
HY-161126 EGFR-IN-98 Inhibitor / 否
HY-141640 MS154 Inhibitor / 否
HY-147860 EGFR-IN-61 Inhibitor / 否
HY-146170 Anticancer agent 69 Inhibitor / 否
HY-146473 EGFR-IN-53 Inhibitor / 否
HY-155074 EGFR-IN-79 Inhibitor / 否
HY-149530 EGFR-IN-86 Inhibitor / 否
HY-155005 EGFR mutant-IN-2 Inhibitor / 否
HY-146472 EGFR-IN-52 Inhibitor / 否
HY-149632 EGFR/HER2/DHFR-IN-2 Inhibitor / 否
HY-149275 PKM2/PDK1-IN-1 Inhibitor / 否
HY-12008S1 Erlotinib-13C6 hydrochloride / 否
HY-160682 EGFR/HER2-IN-12 Inhibitor / 否
HY-155118 EGFR-IN-81 Inhibitor / 否
HY-P1085 Epidermal Growth Factor Receptor Peptide (985-996) Chemical / 否
HY-143445 EGFR-IN-48 Inhibitor / 否
HY-110328 PKI-166 hydrochloride Inhibitor / 否
HY-161145 EGFR/microtubule-IN-1 Inhibitor / 否
HY-112474 Tyrphostin AG 112 Inhibitor 98.55% 否
HY-163420 HER2-IN-16 Inhibitor / 否
HY-P4082 ErbB-2-binding peptide / 否
HY-121828 TX-1123 Inhibitor / 否
HY-151154 EGFR/HER2/DHFR-IN-1 Inhibitor / 否
HY-50896S1 Erlotinib-13C6 Inhibitor / 否
HY-132259 Depatuxizumab mafodotin / 否
HY-162299 EGFR kinase inhibitor 3 Inhibitor / 否
HY-161603 EGFR/HER2-IN-14 Inhibitor / 否
HY-146132 EGFR-IN-55 Inhibitor / 否
HY-149401 EGFR-IN-82 Inhibitor / 否
HY-50898S Lapatinib-d4 Inhibitor 99.02% 否
HY-50898S2 Lapatinib-d5 Inhibitor / 否
HY-155178 Antiproliferative agent-34 Inhibitor / 否
HY-152019 EGFR/C797S-IN-1 Inhibitor / 否
HY-161045 T-1-DOCA Inhibitor / 否
HY-150905 EGFR ligand-2 Inhibitor / 否
HY-P2673 Lys-Arg-Thr-Leu-Arg-Arg / 否
HY-149633 EGFR/HER2/DHFR-IN-3 Inhibitor / 否
HY-10261S1 Afatinib-d4 Inhibitor / 否
HY-163377 AZ5385 Inhibitor / 否
HY-101820A Simotinib hydrochloride Inhibitor / 否
HY-151162 HER2-IN-12 Inhibitor / 否
HY-156115 EGFR/CDK2-IN-3 Inhibitor / 否
HY-156639 EGFR/ErbB-2 inhibitor-1 Inhibitor / 否
HY-146138 EGFR-IN-57 Inhibitor / 否
HY-115952 EGFR/HER2-IN-3 Inhibitor / 否
HY-15268 PP487 Inhibitor / 否
HY-146154 EGFR-IN-58 Inhibitor / 否
HY-161067 EGFR-IN-96 Inhibitor / 否
HY-163006 EGFR/c-Met-IN-1 Inhibitor / 否
HY-149344 Anticancer agent 133 Inhibitor / 否
HY-W008914 (E/Z)-CP-724714 Inhibitor / 否
HY-50898S1 Lapatinib-d7 dihydrochloride Inhibitor / 否
HY-147862 EGFR-IN-62 Inhibitor / 否
HY-144053 EGFR-IN-36 Inhibitor / 否
HY-156033 EGFR-IN-88 Inhibitor / 否
HY-157912 EGFR-IN-102 Inhibitor / 否
HY-144051 EGFR-IN-34 Inhibitor / 否
HY-142679 EGFR-IN-22 Inhibitor / 否
HY-151573 EGFR/CDK2-IN-1 Inhibitor / 否
HY-147797 EGFR/HER2/CDK9-IN-2 Inhibitor / 否
HY-15769A WHI-P180 hydrochloride Inhibitor / 否
HY-50895S2 Gefitinib-d3 Inhibitor / 否
HY-18957B Lifirafenib maleate Inhibitor / 否
HY-163396 EGFR-IN-107 Inhibitor / 否
HY-123766 EGFR-IN-99 Inhibitor / 否
HY-157579 MS154N / 否
HY-137433A Befotertinib mesylate Inhibitor / 否
HY-117523 (Z)-RG-13022 Inhibitor / 否
HY-32721S Neratinib-d6 Inhibitor / 否
HY-15375 Allitinib Inhibitor / 否
HY-146262 LDC0496 Inhibitor / 否
HY-100520 EGFR-IN-2 Inhibitor / 否
HY-111415 EGFR-IN-5 Inhibitor / 否
抗体抑制剂 (7)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P9912A Pertuzumab (PBS) Inhibitor 99.10% 否
HY-P99684 Laprituximab Inhibitor 95.00% 否
HY-P99888 Pimurutamab / 否
HY-P99324 Tomuzotuximab Inhibitor / 否
HY-P99892 Serclutamab 99.97% 否
HY-P990055 Nezutatug Inhibitor / 否
HY-P99558 Timigutuzumab Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens EGFR NCBI NCBI:1956
Macaca fascicularis EGFR NCBI NCBI:102138724
Mus musculus EGFR NCBI NCBI:13649
Rattus norvegicus EGFR NCBI NCBI:24329
Macaca mulatta EGFR NCBI NCBI:613027
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z